Supreme Pharmaceuticals Closes $40.25 Million Bought Deal Private Placement of Convertible Debenture Units

Supreme Pharmaceuticals Inc. (TSXV:FIRE) is pleased to announce the closing of its previously announced bought deal private placement of 40,250 convertible debenture units, including the exercise of the Underwriters' over-allotment option, with a syndicate of underwriters, led by Canaccord Genuity Corp., including Beacon Securities Limited, Cormark Securities Inc., Eight Capital, GMP Securities L.P., and PI Financial Corp., for gross proceeds of approximately $40.25 million.

Supreme Commences Production in New Flowering Rooms

Supreme Pharmaceuticals Inc. ("Supreme" or the "Company") (TSXV: FIRE) is pleased to announce 7ACRES has commenced production in the newly constructed flowering rooms recently approved by Health Canada.  Yesterday, over 3,000 plants of a specially selected phenotype of cannabis called "Wappa" were hand-transplanted into the first of three 10,000 sq. ft. flowering rooms.

Supreme to Quadruple Capacity at 7ACRES Hybrid Facility

Supreme Pharmaceuticals Inc. (TSXV: FIRE) is pleased to announce that 7ACRES has completed construction of three additional 10,000 sq. ft. flowering rooms at its Hybrid Facility, and applied to Health Canada for licensing. Subject to Health Canada approval, the additional flowering rooms will quadruple 7ACRES' flowering footprint from 10,000 sq. ft. to 40,000 sq. ft.

About Supreme